Literature DB >> 17999581

"All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.

Philip S Barie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17999581     DOI： 10.1089/sur.2007.9980

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN： 1096-2964            Impact factor:   2.150


× No keyword cloud information.
  6 in total

1.  Randomized clinical trial of activated protein C for the treatment of acute lung injury.

Authors:  Kathleen D Liu; Joseph Levitt; Hanjing Zhuo; Richard H Kallet; Sandra Brady; Jay Steingrub; Mark Tidswell; Mark D Siegel; Graciela Soto; Michael W Peterson; Mark S Chesnutt; Charles Phillips; Ann Weinacker; B Taylor Thompson; Mark D Eisner; Michael A Matthay
Journal:  Am J Respir Crit Care Med       Date:  2008-06-19       Impact factor: 21.405

2.  Low-dose, off-label drotrecogin alfa (xigris) in severe sepsis.

Authors:  Shan Wang; Kristina Dabovic; Ruth S Spector
Journal:  P T       Date:  2008-08

Review 3.  Protective mechanisms of activated protein C in severe inflammatory disorders.

Authors:  Arne P Neyrinck; Kathleen D Liu; James P Howard; Michael A Matthay
Journal:  Br J Pharmacol       Date:  2009-05-14       Impact factor: 8.739

Review 4.  Critical care nephrology: Core Curriculum 2009.

Authors:  Kathleen D Liu
Journal:  Am J Kidney Dis       Date:  2009-03-20       Impact factor: 8.860

5.  APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial.

Authors:  Ville Pettilä; Lea Kyhälä; Marja-Leena Kylänpää; Ari Leppäniemi; Minna Tallgren; Antti Markkola; Pauli Puolakkainen; Heikki Repo; Esko Kemppainen
Journal:  Crit Care       Date:  2010-07-27       Impact factor: 9.097

6.  Protein C as a surrogate end-point for clinical trials of sepsis.

Authors:  Kathleen D Liu; Michael A Matthay
Journal:  Crit Care       Date:  2008-04-24       Impact factor: 9.097
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.